California · AMD · San Francisco · MIT Technology Review
The PRIMA system, which was approved in Europe in July and is awaiting FDA clearance in the US, changes
Compiled by KHAO Editorial — aggregated from 1 source. See llms.txt for citation guidance.
◌ Single Source
After training sessions, more than 80% of recipients were able to read, do crosswords, and use their phones.
Key facts
- More than 5 million people around the world with age-related macular degeneration (AMD) experience atrophy in their retinas
- The video feed is roughly five megapixels running at 30 frames per second, which is similar to TV
- The PRIMA system, which was approved in Europe in July and is awaiting FDA clearance in the US, changes
- After training sessions, more than 80% of recipients were able to read, do crosswords, and use their phones
Summary
More than 5 million people around the world with age-related macular degeneration (AMD) experience atrophy in their retinas. The PRIMA system, which was approved in Europe in July and is awaiting FDA clearance in the US, changes that. Developed by the California-based Science Corporation, the system takes advantage of the fact that AMD doesn’t damage all retinal circuitry; only photoreceptors—the cells that convert light into an electrical signal—die off. Glasses outfitted with a miniature front-facing camera capture what someone is seeing in real time. A small, handheld processor, which can be set on a table or tucked in a pocket, converts the video feed into infrared light signals that route back to the glasses. A laser projector on the glasses faces the wearer and shines pulses of near-infrared light directly at the eye at 880 nanometers—an invisible wavelength.